


Applicant : Coy *et al.*
Serial No. : 10/712,081
Filed : November 13, 2003
Page : 2

COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS
(Amendments are illustrated by showing deletions by ~~striketrough~~ or by [[double brackets]] for deletions of five or fewer characters and additions by underlining)

Claims 1-22 (canceled)

23 (currently amended): A compound of the formula:



wherein

A¹ is a D- or L-isomer of an aromatic amino acid, or is deleted;

~~A² is a D aromatic amino acid,~~

~~A³ is an aromatic amino acid,~~

~~A⁶ is Thr, Thr(Bzl), Gly, Ser, an Eaa, or an aliphatic amino acid,~~

~~A⁷ is an aromatic amino acid or an aliphatic amino acid,~~

A⁸ is a D- or L-isomer selected from the group consisting of Thr, Ser, an aromatic amino acid, or an aliphatic amino acid;

each of R₁ and R₂, is, independently, H or substituted or unsubstituted lower alkyl, aryl, aryl lower alkyl, heterocycle, heterocycle lower alkyl, E₁SO₂, or E₁CO wherein E₁ is aryl, aryl lower alkyl, heterocycle, or heterocycle lower alky and said substituent is halo, lower alkyl, hydroxy, halo lower alkyl, or hydroxy lower alkyl; and

Applicant : Coy *et al.*
Serial No. : 10/712,081
Filed : November 13, 2003
Page : 3

R_3 is OH, NH_2 , C_{1-12} alkoxy, or $NH-Y-CH_2-Z$, wherein Y is a C_{1-12} hydrocarbon moiety and Z is H, OH, CO_2H , or $CONH_2$, or R_3 , together with the carbonyl group of A^8 attached thereto, are reduced to form H, lower alkyl, or hydroxy lower alkyl.

24 (currently amended): A compound of claim 23,
wherein A^1 is an L-amino acid and ~~A^2 is a D-aromatic amino acid.~~

25-26 (canceled)

27 (currently amended): A compound of claim [[25]] 24
of the formula:

~~H_2 -Phe-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr- NH_2~~

~~H_2 -Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr- NH_2~~

H_2 -Phe-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr- NH_2 ;

H_2 - β -Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr- NH_2 ;

(H) $(CH_3CO)-\beta$ -Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr- NH_2 ;

(H) $(4-(2\text{-hydroxyethyl})-1\text{-piperazinylacetyl})-\beta$ -Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr- NH_2 ;

(H) $(4-(2\text{-hydroxyethyl})-1\text{-piperizineethanesulfonyl})-\beta$ -Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr- NH_2 ;

~~H_2 - β -Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr- NH_2~~

~~(H) $(CH_3CO)-\beta$ -Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr- NH_2~~

~~(H) $(4-(2\text{-hydroxyethyl})-1\text{-piperazinylacetyl})-\beta$ -Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr- NH_2~~

Applicant : Coy et al.
Serial No. : 10/712,081
Filed : November 13, 2003
Page : 4

~~(H) (4- (2-hydroxyethyl)-1-piperizineethanesulfonyl)- β -Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH₂;~~
~~H₂- β -Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH₂;~~
~~(H) (CH₃CO)- β -Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH₂;~~
~~(H) (4- (2-hydroxyethyl)-1-piperazinylacetyl)- β -Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH₂;~~
~~(H) (4- (2-hydroxyethyl)-1-piperizineethanesulfonyl)- β -Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH₂;~~
~~H₂- β -Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH₂;~~
~~(H) (CH₃CO)- β -Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH₂;~~
~~(H) (4- (2-hydroxyethyl)-1-piperazinylacetyl)- β -Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH₂;~~
~~(H) (4- (2-hydroxyethyl)-1-piperizineethanesulfonyl)- β -Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH₂;~~
~~H₂- β -Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe- β -Nal-NH₂;~~
~~(H) (CH₃CO)- β -Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe- β -Nal-NH₂;~~
~~(H) (4- (2-hydroxyethyl)-1-piperazinylacetyl)- β -Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe- β -Nal-NH₂;~~
~~(H) (4- (2-hydroxyethyl)-1-piperizineethanesulfonyl)- β -Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe- β -Nal-NH₂;~~
~~H₂- β -Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe- β -Nal-NH₂;~~ or
~~H₂- β -Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;~~ or
a pharmaceutically acceptable salt thereof.

28 (currently amended): A compound of claim 23,
wherein A¹ is a D-amino acid and ~~A² is a D-aromatic amino acid.~~

29-30 (canceled)

31 (currently amended): A compound of claim [[29]] 28
of the formula:

~~H₂-D-β-Nal-D-Cpa-Phe-D-Trp-Lys-Val-Phe-Thr-NH₂~~

~~H₂-D-β-Nal-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH₂~~

~~H₂-D-Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂~~

H₂-D-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂; or

H₂-D-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH₂; or

a pharmaceutically acceptable salt thereof.

32 (withdrawn-currently amended): A method of
promoting the release of growth hormone in a subject in need
thereof, which comprises administering to said subject an
effective amount of a compound according to claim [[18]] 23 or a
pharmaceutically acceptable salt thereof.

33 (withdrawn-currently amended): A method of
promoting the release of insulin in a subject in need thereof,
which comprises administering to said subject an effective amount
of a compound according to claim [[18]] 23 or a pharmaceutically
acceptable salt thereof.

34 (withdrawn-currently amended): A method of
enhancing wound healing in a subject in need thereof, which

Applicant : Coy *et al.*
Serial No. : 10/712,081
Filed : November 13, 2003
Page : 6

comprises administering to said subject an effective amount of a compound according to claim ~~[[18]]~~ 23 or a pharmaceutically acceptable salt thereof.

35 (withdrawn-currently amended): A method of promoting angiogenesis in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim ~~[[18]]~~ 23 or a pharmaceutically acceptable salt thereof.

36 (canceled)

37 (withdrawn-currently amended): A method of eliciting an antagonist effect from a somatostatin receptor in a subject, which comprises administering to said subject an effective amount of a compound according to claim ~~[[18]]~~ 23 or a pharmaceutically acceptable salt thereof.

38-44 (canceled)

45 (new): A compound of the formula:

H₂-Phe-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH₂; or

H₂-Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂; or a

pharmaceutically acceptable salt thereof.

Applicant : Coy *et al.*
Serial No. : 10/712,081
Filed : November 13, 2003
Page : 7

46 (new): A method of promoting the release of growth hormone in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 45 or a pharmaceutically acceptable salt thereof.

47 (new): A method of promoting the release of insulin in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 45 or a pharmaceutically acceptable salt thereof.

48 (new): A method of enhancing wound healing in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 45 or a pharmaceutically acceptable salt thereof.

49 (new): A method of promoting angiogenesis in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 45 or a pharmaceutically acceptable salt thereof.

50 (new): A method of eliciting an antagonist effect from a somatostatin receptor in a subject, which comprises administering to said subject an effective amount of a compound according to claim 45 or a pharmaceutically acceptable salt thereof.